175 related articles for article (PubMed ID: 37986208)
1. Genomic and Molecular Characteristics of Ovarian Carcinosarcoma.
Ramphal K; Hadfield MJ; Bandera CM; Hart J; Dizon DS
Am J Clin Oncol; 2023 Dec; 46(12):572-576. PubMed ID: 37986208
[TBL] [Abstract][Full Text] [Related]
2. Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a poly (adenosine diphosphate [ADP]- ribose) polymerase (PARP) inhibitor.
Tymon-Rosario JR; Manara P; Manavella DD; Bellone S; Hartwich TMP; Harold J; Yang-Hartwich Y; Zipponi M; Choi J; Jeong K; Mutlu L; Yang K; Altwerger G; Menderes G; Ratner E; Huang GS; Clark M; Andikyan V; Azodi M; Schwartz PE; Alexandrov LB; Santin AD
Gynecol Oncol; 2022 Jul; 166(1):117-125. PubMed ID: 35599167
[TBL] [Abstract][Full Text] [Related]
3. "Carcinosarcoma of the ovary, fallopian tube, and peritoneum: Prognostic factors and treatment modalities".
Rauh-Hain JA; Birrer M; Del Carmen MG
Gynecol Oncol; 2016 Aug; 142(2):248-54. PubMed ID: 27321238
[TBL] [Abstract][Full Text] [Related]
4. Defective DNA repair in hereditary ovarian cancers: Implications for therapy.
Burgess BT; Kolesar JM
Am J Health Syst Pharm; 2018 Nov; 75(21):1697-1707. PubMed ID: 30228165
[TBL] [Abstract][Full Text] [Related]
5. Epithelial-to-Mesenchymal Transition Supports Ovarian Carcinosarcoma Tumorigenesis and Confers Sensitivity to Microtubule Targeting with Eribulin.
Ho GY; Kyran EL; Bedo J; Wakefield MJ; Ennis DP; Mirza HB; Vandenberg CJ; Lieschke E; Farrell A; Hadla A; Lim R; Dall G; Vince JE; Chua NK; Kondrashova O; Upstill-Goddard R; Bailey UM; Dowson S; Roxburgh P; Glasspool RM; Bryson G; Biankin AV; ; Cooke SL; Ratnayake G; McNally O; Traficante N; ; DeFazio A; Weroha SJ; Bowtell DD; McNeish IA; Papenfuss AT; Scott CL; Barker HE
Cancer Res; 2022 Dec; 82(23):4457-4473. PubMed ID: 36206301
[TBL] [Abstract][Full Text] [Related]
6. An update on current and emerging therapies for epithelial ovarian cancer: Focus on poly(adenosine diphosphate-ribose) polymerase inhibition and antiangiogenesis.
Chung C; Lee R
J Oncol Pharm Pract; 2017 Sep; 23(6):454-469. PubMed ID: 27357817
[TBL] [Abstract][Full Text] [Related]
7. Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment.
Papa A; Caruso D; Strudel M; Tomao S; Tomao F
J Transl Med; 2016 Sep; 14():267. PubMed ID: 27634150
[TBL] [Abstract][Full Text] [Related]
8. Frontiers of Ovarian Carcinosarcoma.
Ismail A; Choi S; Boussios S
Curr Treat Options Oncol; 2023 Dec; 24(12):1667-1682. PubMed ID: 37938504
[TBL] [Abstract][Full Text] [Related]
9. Carcinosarcoma of the ovary: a review of the literature.
del Carmen MG; Birrer M; Schorge JO
Gynecol Oncol; 2012 Apr; 125(1):271-7. PubMed ID: 22155675
[TBL] [Abstract][Full Text] [Related]
10. Conventional chemotherapy and oncogenic pathway targeting in ovarian carcinosarcoma using a patient-derived tumorgraft.
Glaser G; Weroha SJ; Becker MA; Hou X; Enderica-Gonzalez S; Harrington SC; Haluska P
PLoS One; 2015; 10(5):e0126867. PubMed ID: 25962155
[TBL] [Abstract][Full Text] [Related]
11. Randomized, two-arm, noncomparative phase 2 study of olaparib plus cediranib or durvalumab in HRR-mutated, platinum-resistant ovarian cancer: A substudy of KGOG 3045.
Kim YN; Joung JG; Park E; Kim JW; Lee JB; Lim J; Kim S; Choi CH; Kim HS; Chung J; Kim BG; Lee JY
Int J Cancer; 2023 Dec; 153(12):2032-2044. PubMed ID: 37602928
[TBL] [Abstract][Full Text] [Related]
12. Small Cell and Other Rare Histologic Types of Cervical Cancer.
Marchocki Z; Swift B; Covens A
Curr Oncol Rep; 2022 Nov; 24(11):1531-1539. PubMed ID: 35947285
[TBL] [Abstract][Full Text] [Related]
13. Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
Parkes EE; Kennedy RD
Oncologist; 2016 May; 21(5):586-93. PubMed ID: 27022037
[TBL] [Abstract][Full Text] [Related]
14. Current management of ovarian carcinosarcoma.
Mano MS; Rosa DD; Azambuja E; Ismael G; Braga S; D'Hondt V; Piccart M; Awada A
Int J Gynecol Cancer; 2007; 17(2):316-24. PubMed ID: 17362309
[TBL] [Abstract][Full Text] [Related]
15. Platinum, anthracycline, and alkylating agent-based chemotherapy for ovarian carcinosarcoma.
Signorelli M; Chiappa V; Minig L; Fruscio R; Perego P; Caspani G; Battistello M; Colombo N
Int J Gynecol Cancer; 2009 Aug; 19(6):1142-6. PubMed ID: 19820383
[TBL] [Abstract][Full Text] [Related]
16. Patterns of care, predictors and outcomes of chemotherapy for ovarian carcinosarcoma: A National Cancer Database analysis.
Rauh-Hain JA; Gonzalez R; Bregar AJ; Clemmer J; Hernández-Blanquisett A; Clark RM; Schorge JO; Del Carmen MG
Gynecol Oncol; 2016 Jul; 142(1):38-43. PubMed ID: 27107722
[TBL] [Abstract][Full Text] [Related]
17. Plectin-targeted liposomes enhance the therapeutic efficacy of a PARP inhibitor in the treatment of ovarian cancer.
Dasa SSK; Diakova G; Suzuki R; Mills AM; Gutknecht MF; Klibanov AL; Slack-Davis JK; Kelly KA
Theranostics; 2018; 8(10):2782-2798. PubMed ID: 29774075
[TBL] [Abstract][Full Text] [Related]
18. [Abnormalities of DNA repair and gynecological cancers].
Auguste A; Leary A
Bull Cancer; 2017 Nov; 104(11):971-980. PubMed ID: 29054544
[TBL] [Abstract][Full Text] [Related]
19. Poly (ADP-ribose) polymerase inhibitors in the management of ovarian cancer.
Markman M
Womens Health (Lond); 2018; 14():1745505717750694. PubMed ID: 29313444
[TBL] [Abstract][Full Text] [Related]
20. The current status of PARP inhibitors in ovarian cancer.
McLachlan J; George A; Banerjee S
Tumori; 2016 Oct; 102(5):433-440. PubMed ID: 27716873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
